CO5560576A2 - Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades - Google Patents
Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedadesInfo
- Publication number
- CO5560576A2 CO5560576A2 CO04016657A CO04016657A CO5560576A2 CO 5560576 A2 CO5560576 A2 CO 5560576A2 CO 04016657 A CO04016657 A CO 04016657A CO 04016657 A CO04016657 A CO 04016657A CO 5560576 A2 CO5560576 A2 CO 5560576A2
- Authority
- CO
- Colombia
- Prior art keywords
- lower alkyl
- heterocyclyl
- cycloalkyl
- aryl
- molecule
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000004432 carbon atom Chemical group C* 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 abstract 3
- -1 R6 is H Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 229910052717 sulfur Inorganic materials 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000005257 alkyl acyl group Chemical group 0.000 abstract 1
- 125000003368 amide group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000005251 aryl acyl group Chemical group 0.000 abstract 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 150000002829 nitrogen Chemical class 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0121024A GB0121024D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
| GBGB0121026.9A GB0121026D0 (en) | 2001-08-30 | 2001-08-30 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5560576A2 true CO5560576A2 (es) | 2005-09-30 |
Family
ID=26246490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04016657A CO5560576A2 (es) | 2001-08-30 | 2004-02-25 | Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7112589B2 (enExample) |
| EP (1) | EP1423121B1 (enExample) |
| JP (1) | JP4131701B2 (enExample) |
| KR (1) | KR100629834B1 (enExample) |
| CN (1) | CN1549717B (enExample) |
| AR (1) | AR036375A1 (enExample) |
| AT (1) | ATE345136T1 (enExample) |
| AU (1) | AU2002333758B2 (enExample) |
| BR (1) | BR0212141A (enExample) |
| CA (1) | CA2456127C (enExample) |
| CO (1) | CO5560576A2 (enExample) |
| DE (1) | DE60216122T2 (enExample) |
| ES (1) | ES2275946T3 (enExample) |
| HU (1) | HUP0401431A3 (enExample) |
| IL (1) | IL160295A0 (enExample) |
| MX (1) | MXPA04001930A (enExample) |
| NZ (1) | NZ531287A (enExample) |
| PE (1) | PE20030772A1 (enExample) |
| PL (1) | PL208280B1 (enExample) |
| PT (1) | PT1423121E (enExample) |
| RU (1) | RU2326119C2 (enExample) |
| WO (1) | WO2003020278A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201976D0 (sv) * | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| GB0220187D0 (en) | 2002-08-30 | 2002-10-09 | Novartis Ag | Organic compounds |
| WO2005014006A1 (en) * | 2003-07-21 | 2005-02-17 | Novartis Ag | Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| WO2005011703A1 (en) * | 2003-08-04 | 2005-02-10 | Akzo Nobel N.V. | 2-cyano-1,3,5-triazine-4,6-diamine derivatives |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| WO2005049028A1 (en) * | 2003-11-19 | 2005-06-02 | Novartis Ag | Use of cathepsin k inhibitors in severe bone loss diseases |
| US20070232586A1 (en) * | 2004-04-21 | 2007-10-04 | Kazuyuki Ohmoto | Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof |
| TW200614993A (en) * | 2004-06-11 | 2006-05-16 | Akzo Nobel Nv | 4-phenyl-pyrimidine-2-carbonitrile derivatives |
| WO2006027211A1 (en) * | 2004-09-07 | 2006-03-16 | Glaxo Group Limited | 2,4-substituted pyrimidines as cysteine protease inhibitors |
| WO2006040300A1 (en) * | 2004-10-12 | 2006-04-20 | N.V. Organon | 4-cycloalkyl-pyrimidine-2-carbonitrile derivatives |
| IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
| GB0514684D0 (en) * | 2005-07-18 | 2005-08-24 | Novartis Ag | Organic compounds |
| CA2617725C (en) * | 2005-08-05 | 2012-04-03 | Hybrigenics Sa | Novel cysteine protease inhibitors and their therapeutic applications |
| WO2007025776A2 (en) * | 2005-09-02 | 2007-03-08 | Glaxo Group Limited | Cysteine protease inhibitors |
| US7326715B2 (en) | 2005-09-23 | 2008-02-05 | N.V. Organon | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| TW200745055A (en) * | 2005-09-23 | 2007-12-16 | Organon Nv | 4-Phenyl-6-substituted-pyrimidine-2-carbonitrile derivatives |
| US7687515B2 (en) | 2006-01-17 | 2010-03-30 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| CA2652600A1 (en) * | 2006-05-22 | 2007-11-29 | Velcura Therapeutics, Inc. | Use of cathepsin k antagonists in bone production |
| US20090227579A1 (en) * | 2006-06-23 | 2009-09-10 | Astrazeneca Ab | Pteridine Derivatives and their Use as Cathespin Inhibitors |
| EP1947091A1 (en) * | 2007-01-16 | 2008-07-23 | Glaxo Group Limited | Pyrimidyl nitrile derivatives as cysteine protease inhibitors |
| US7932251B2 (en) | 2007-07-16 | 2011-04-26 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2489656A1 (en) | 2007-12-21 | 2012-08-22 | Ligand Pharmaceuticals Inc. | Selective androgen receptor modulators (sarms) and uses thereof |
| WO2009087379A2 (en) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases |
| TW201035094A (en) | 2009-01-16 | 2010-10-01 | Organon Nv | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| US8026236B2 (en) | 2009-01-16 | 2011-09-27 | N.V. Organon | 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP2316820A1 (en) * | 2009-10-28 | 2011-05-04 | Dompe S.p.A. | 2-aryl-propionamide derivatives useful as bradykinin receptor antagonists and pharmaceutical compositions containing them |
| US9115126B2 (en) | 2010-01-15 | 2015-08-25 | Merck Sharp & Dohme B.V. | 1H-[1,2,3]triazolo[4,5-c]pyridine-4-carbonitrile derivatives |
| EP3091085B1 (en) | 2010-10-06 | 2019-02-27 | Institució Catalana de Recerca I Estudis Avançats | Method of designing a therapy for breast cancer metastasis |
| US8524710B2 (en) * | 2010-11-05 | 2013-09-03 | Hoffmann-La Roche Inc. | Pyrrolidine derivatives |
| EP2650682A1 (en) | 2012-04-09 | 2013-10-16 | Fundació Privada Institut de Recerca Biomèdica | Method for the prognosis and treatment of cancer metastasis |
| BR112014030750A2 (pt) | 2012-06-06 | 2017-08-22 | Inst Catalana Recerca Estudis Avancats | Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| US20140105918A1 (en) | 2012-10-12 | 2014-04-17 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| CA2906394A1 (en) | 2013-03-15 | 2014-09-18 | Fundacio Institut De Recerca Biomedica (Irb Barcelona) | Method for the prognosis and treatment of cancer metastasis |
| US20160032399A1 (en) | 2013-03-15 | 2016-02-04 | Inbiomotion S.L. | Method for the Prognosis and Treatment of Renal Cell Carcinoma Metastasis |
| MX362041B (es) | 2013-10-09 | 2019-01-07 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Método para el pronóstico y tratamiento de cáncer metastásico de los huesos originado de cáncer de mama. |
| EP3094323A4 (en) | 2014-01-17 | 2017-10-11 | Ligand Pharmaceuticals Incorporated | Methods and compositions for modulating hormone levels |
| CA2967224C (en) | 2014-12-11 | 2023-08-22 | Inbiomotion S.L. | Binding members for human c-maf |
| DK3458610T3 (da) | 2016-05-25 | 2021-06-07 | Inbiomotion Sl | Terapeutisk behandling af brystcancer baseret på c-MAF-status |
| WO2018138356A1 (en) * | 2017-01-27 | 2018-08-02 | Genfit | Rorgamma modulators and uses thereof |
| CN108586356B (zh) * | 2017-03-16 | 2021-02-19 | 杭州科巢生物科技有限公司 | 瑞博西尼新中间体及其制备瑞博西尼的合成方法 |
| AU2018372762B2 (en) | 2017-11-22 | 2025-08-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
| CN109467536B (zh) * | 2018-12-23 | 2020-06-05 | 沧州普瑞东方科技有限公司 | 2-氯/羟基嘧啶-5-羧酸的合成方法 |
| WO2020201572A1 (en) | 2019-04-05 | 2020-10-08 | Université De Bretagne Occidentale | Protease-activated receptor-2 inhibitors for the treatment of sensory neuropathy induced by a marine neurotoxic poisoning |
| CA3133929A1 (en) | 2019-04-19 | 2020-10-22 | Lin Zhi | Crystalline forms and methods of producing crystalline forms of a compound |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL270922A (enExample) | 1960-11-02 | |||
| NL295648A (enExample) * | 1962-07-26 | |||
| BR6915234D0 (pt) | 1969-05-22 | 1973-06-07 | American Cyanamid Co | Novos derivados de melamina e processo para sua preparaca |
| CH627919A5 (de) * | 1977-04-14 | 1982-02-15 | Ciba Geigy Ag | Herbizide mittel. |
| WO1997009315A1 (en) * | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
| AU1608397A (en) | 1996-02-02 | 1997-08-22 | Zeneca Limited | Heterocyclic compounds useful as pharmaceutical agents |
| DE19817459A1 (de) | 1998-04-20 | 1999-10-21 | Basf Ag | Neue heterozyklische substituierte Amide, Herstellung und Anwendung |
| HUP0302380A2 (hu) | 1999-09-13 | 2004-03-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cisztein-proteázok reverzibilis inhibitoraiként alkalmazható új spiroheterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| IL148291A0 (en) * | 1999-09-16 | 2002-09-12 | Tanabe Seiyaku Co | Aromatic nitrogen-containing 6-membered cyclic compounds |
| CN1440393A (zh) * | 2000-04-28 | 2003-09-03 | 田边制药株式会社 | 环状化合物 |
| GB0013383D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| AR036375A1 (es) * | 2001-08-30 | 2004-09-01 | Novartis Ag | Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0201976D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
-
2002
- 2002-08-28 AR ARP020103230A patent/AR036375A1/es not_active Application Discontinuation
- 2002-08-29 PL PL367821A patent/PL208280B1/pl not_active IP Right Cessation
- 2002-08-29 US US10/487,741 patent/US7112589B2/en not_active Expired - Fee Related
- 2002-08-29 BR BR0212141-7A patent/BR0212141A/pt not_active IP Right Cessation
- 2002-08-29 AU AU2002333758A patent/AU2002333758B2/en not_active Ceased
- 2002-08-29 EP EP02797650A patent/EP1423121B1/en not_active Expired - Lifetime
- 2002-08-29 ES ES02797650T patent/ES2275946T3/es not_active Expired - Lifetime
- 2002-08-29 KR KR1020047002973A patent/KR100629834B1/ko not_active Expired - Fee Related
- 2002-08-29 IL IL16029502A patent/IL160295A0/xx unknown
- 2002-08-29 PE PE2002000834A patent/PE20030772A1/es not_active Application Discontinuation
- 2002-08-29 HU HU0401431A patent/HUP0401431A3/hu unknown
- 2002-08-29 CN CN028169638A patent/CN1549717B/zh not_active Expired - Fee Related
- 2002-08-29 RU RU2004109812/04A patent/RU2326119C2/ru not_active IP Right Cessation
- 2002-08-29 AT AT02797650T patent/ATE345136T1/de active
- 2002-08-29 MX MXPA04001930A patent/MXPA04001930A/es active IP Right Grant
- 2002-08-29 DE DE60216122T patent/DE60216122T2/de not_active Expired - Lifetime
- 2002-08-29 CA CA002456127A patent/CA2456127C/en not_active Expired - Fee Related
- 2002-08-29 NZ NZ531287A patent/NZ531287A/en unknown
- 2002-08-29 JP JP2003524585A patent/JP4131701B2/ja not_active Expired - Fee Related
- 2002-08-29 PT PT02797650T patent/PT1423121E/pt unknown
- 2002-08-29 WO PCT/EP2002/009661 patent/WO2003020278A1/en not_active Ceased
-
2004
- 2004-02-25 CO CO04016657A patent/CO5560576A2/es not_active Application Discontinuation
-
2005
- 2005-11-30 US US11/291,007 patent/US20060074092A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04001930A (es) | 2004-06-15 |
| DE60216122T2 (de) | 2007-09-06 |
| ES2275946T3 (es) | 2007-06-16 |
| KR20040029101A (ko) | 2004-04-03 |
| CN1549717B (zh) | 2011-08-17 |
| CA2456127C (en) | 2009-10-20 |
| JP2005505550A (ja) | 2005-02-24 |
| WO2003020278A1 (en) | 2003-03-13 |
| DE60216122D1 (de) | 2006-12-28 |
| AR036375A1 (es) | 2004-09-01 |
| PL208280B1 (pl) | 2011-04-29 |
| PT1423121E (pt) | 2007-02-28 |
| BR0212141A (pt) | 2004-08-24 |
| KR100629834B1 (ko) | 2006-09-29 |
| US7112589B2 (en) | 2006-09-26 |
| NZ531287A (en) | 2005-12-23 |
| US20060074092A1 (en) | 2006-04-06 |
| AU2002333758B2 (en) | 2006-01-19 |
| PE20030772A1 (es) | 2003-10-02 |
| ATE345136T1 (de) | 2006-12-15 |
| HUP0401431A2 (hu) | 2004-10-28 |
| IL160295A0 (en) | 2004-07-25 |
| PL367821A1 (en) | 2005-03-07 |
| CA2456127A1 (en) | 2003-03-13 |
| EP1423121A1 (en) | 2004-06-02 |
| RU2326119C2 (ru) | 2008-06-10 |
| RU2004109812A (ru) | 2005-10-20 |
| JP4131701B2 (ja) | 2008-08-13 |
| US20040249153A1 (en) | 2004-12-09 |
| HUP0401431A3 (en) | 2004-11-29 |
| EP1423121B1 (en) | 2006-11-15 |
| CN1549717A (zh) | 2004-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5560576A2 (es) | Inhibidores de proteasa de cisteina con estructura de 2- ciano 4-amino-pirimidina y actividad inhibidora de captesina k para el tratamiento de inflamaciones y otras enfermedades | |
| JP2005505550A5 (enExample) | ||
| PA8431301A1 (es) | Inhibidores de metaloproteinasas, composiciones farmaceuticas que los contienen y sus usos farmaceuticos y los metodos e intermedios utiles para su preparacion | |
| AR036374A1 (es) | Pirrolo pirimidinas. | |
| BR0211910A (pt) | Derivados de tiazolila 2,4,5-trissubstituìdos e a atividade antiinflamatória dos mesmos | |
| EP1070710A3 (en) | Dithiolan derivatives, their preparation and their therapeutic effect | |
| ES2077948T3 (es) | Preparacion para el cuidado externo de la piel. | |
| EA199800074A1 (ru) | Бициклические аминопроизводные и содержащие их антагонисты pgd | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| FR2754260B1 (fr) | Nouveaux derives substitues de biphenyle ou de phenylpyridine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| KR960007545A (ko) | 합성 흥분성 아미노산 | |
| AR246963A1 (es) | Un procedimiento para la preparacion de nuevos derivados de triazol. | |
| CO5021129A1 (es) | Nuevos compuestos farmaceuticos derivados de pleuromutilina y metodos para su preparacion | |
| NO20044038L (no) | Glutaminylbaserte DRIV-inhibitorer | |
| NO2012015I1 (no) | Dapoxetine i en hver form beskyttet av basis patent nr 330562 | |
| AR035732A1 (es) | Derivados cromen-2-carboxilicos terapeuticos, uso de estos derivados para la preparacion de medicamentos, composicion farmaceutica, compuestos relacionados, y procesos para preparar estos compuestos relacionados | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| KR940005568A (ko) | 1-아미노아세트아미도피롤, 1-아미노 아세트아미도-2-(치환된)피롤 및 관련 화합물 | |
| AR035230A1 (es) | Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos | |
| DK0659193T3 (da) | Blodpladeaggregationsinhibitorer | |
| AR030197A1 (es) | Compuesto n-sustituido que contiene una cadena lateral heterociclica, composicion farmaceutica que lo comprende y uso de dicho compuesto para la fabricacion de un medicamento | |
| AR042284A1 (es) | Derivados de piperidina, preparacion y composiciones farmaceuticas que las contienen; y uso de los mismos para la fabricacion de medicamentos | |
| ES2177727T3 (es) | Derivados de 4-indolilpiperazinilo. | |
| AR035685A1 (es) | Derivados de isoxazolina, sus prodrogas, composiciones farmaceuticas que comprenden dichos compuestos, procesos para preparar dichas composiciones, uso de dichos compuestos para la fabricacion de medicamentos, uso de dichas composiciones para la fabricacion de medicamentos, procesos para la preparac | |
| DK0517876T3 (da) | Terapeutiske benzazepinforbindelser |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |